New drug radiprodil tested for tough seizures in two brain conditions
NCT ID NCT06392009
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests an experimental drug called radiprodil in 30 people with tuberous sclerosis complex or focal cortical dysplasia type II whose seizures have not responded to at least two other medications. The study is open-label, meaning everyone gets the drug, and will check safety, how the body processes the drug, and whether it reduces seizures and behavioral symptoms over up to one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radiprodil
What this could lead to
If it works, this could point toward a new treatment option for hard-to-control seizures in people with TSC or FCD type II.
What could go wrong
This is an early, small, open-label study with no placebo group, so results may not prove effectiveness. Side effects are still being identified.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBEROUS SCLEROSIS COMPLEX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AOU Meyer
Florence, Tuscany, 50139, Italy
-
Alberta Children's Hospital
Calgary, T3A 2X6, Canada
-
Centrum Medyczne Plejady
Krakow, 30363, Poland
-
Hospital Materno Infantil Sant Joan de Deu de Barcelona
Barcelona, 08950, Spain
-
Hospital Ruber Internacional
Madrid, 28034, Spain
-
Hospital Universitario Vall D´Hebrón
Barcelona, 08035, Spain
-
Hospital Universitario Vithas La Milagrosa
Madrid, 28010, Spain
-
IRCCS Istituto Giannina Gaslini
Genoa, Liguria, 16146, Italy
-
Instytut Pomnik - Centrum Zdrowia Dziecka
Warsaw, 04730, Poland
-
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
Roma, 00165, Italy
-
Queensland Children Hospital
South Brisbane, 4101, Australia
-
The Hospital for Sick Children (Sick Kids)
Toronto, M5G 1X8, Canada
-
UMC Uthrecht - Wilhelmina Kinderziekenhuis
Utrecht, 3508, Netherlands
-
Universita Cattolica del Sacro Cuore - Policlinico Universitario "Agostino Gemelli"
Roma, 00168, Italy
-
University Hospitals Bristol and Weston NHS Foundation Trust Bristol Royal Hospital for Children
Bristol, BS2 8BJ, United Kingdom
-
University Hospitals Leuven, Pediatric Neurology
Leuven, 3000, Belgium
-
Uniwersytecki Szpital Kliniczny w Poznaniu
Poznan, 60356, Poland
-
Uniwersyteckie Centrum Kliniczne
Gdansk, 80952, Poland